Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Open access

Abstract

Background Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis. We hypothesized that baseline gut microbiota could predict ipilimumab anti-tumor response and/or intestinal toxicity. Patients and methods Twenty-six patients with MM treated with ipilimumab were prospectively enrolled. Fecal microbiota composition was assessed using 16S rRNA gene sequencing at baseline and before each ipilimumab infusion. Patients were further clustered based on microbiota patterns. Peripheral blood lymphocytes immunophenotypes were studied in parallel. Results A distinct baseline gut microbiota composition was associated with both clinical response and colitis. Compared with patients whose baseline microbiota was driven by Bacteroides (cluster B, n = 10), patients whose baseline microbiota was enriched with Faecalibacterium genus and other Firmicutes (cluster A, n = 12) had longer progression-free survival (P = 0.0039) and overall survival (P = 0.051). Most of the baseline colitis-associated phylotypes were related to Firmicutes (e.g. relatives of Faecalibacterium prausnitzii and Gemmiger formicilis), whereas no colitis-related phylotypes were assigned to Bacteroidetes. A low proportion of peripheral blood regulatory T cells was associated with cluster A, long-term clinical benefit and colitis. Ipilimumab led to a higher inducible T-cell COStimul…

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx108

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

35 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 46 references

Cited by

See all 1,310

Metadata

Authors
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., Vaysse, T., Marthey, L., Eggermont, A., Asvatourian, V., Lanoy, E., Mateus, C., Robert, C., & Carbonnel, F.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • AgroParisTech (FR)
  • Université Paris-Saclay (FR)
  • Inserm (FR)
  • Université Paris-Sud (FR)
  • Université du Burundi (BI)
Corresponding author
Carbonnel, F.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-06
Volume
28
Issue
6
Pages
1368-1379
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2601055810
Cited by
1,310
References
46
Citations by year
2026: 83 · 2025: 122 · 2024: 146 · 2023: 198 · 2022: 195 · 2021: 194 · 2020: 181 · 2019: 106 · 2018: 63 · 2017: 20
FWCI
44.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
Agence Nationale de la Recherche (ANR-10-IBHU-0001)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
gut microbiota, ipilimumab, metastatic melanoma, immune checkpoint inhibitors, immune-related adverse events, colitis, Faecalibacterium, Firmicutes, Bacteroides, predictive biomarkers, clinical response, regulatory T cells, CD25, CTLA-4, progression-free survival, overall survival
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Aged, Colitis, Female, Humans, Intestines, Male, Melanoma, Neoplasm Metastasis, Prospective Studies, RNA, Ribosomal, 16S, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. https://app.cochat.ai/papers/10.1093/annonc/mdx108
The paper
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., Vaysse, T., Marthey, L., Eggermont, A., Asvatourian, V., Lanoy, E., Mateus, C., Robert, C., & Carbonnel, F. (2017). Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of Oncology. https://doi.org/10.1093/annonc/mdx108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.